ProfileGDS5678 / 1456370_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 69% 66% 69% 73% 69% 66% 70% 69% 72% 66% 62% 69% 68% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.2438669
GSM967853U87-EV human glioblastoma xenograft - Control 24.0075266
GSM967854U87-EV human glioblastoma xenograft - Control 34.2374269
GSM967855U87-EV human glioblastoma xenograft - Control 44.8626273
GSM967856U87-EV human glioblastoma xenograft - Control 54.204669
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0364866
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.3612370
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.2182369
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.60272
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.9596266
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7281162
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.2208469
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.1747668
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.228169